Can-Fite BioPharma Ltd Stock News

Can-Fite BioPharma (CANF) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial for liver cancer. The post CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite

5 penny stocks to buy for under $5 right now. Are they worth the risk?

Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) Research analysts at Dawson James boosted their FY2021 earnings per share estimates for shares of Can-Fite BioPharma in a research note issued on Tuesday, December 7th. Dawson James analyst J. Kolbert now forecasts that the biotechnology company will post earnings of ($0.43) per share for the year, up from their []

Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) Research analysts at Dawson James boosted their FY2021 earnings estimates for shares of Can-Fite BioPharma in a report released on Tuesday, December 7th. Dawson James analyst J. Kolbert now anticipates that the biotechnology company will post earnings of ($0.43) per share for the year, up from their prior estimate of [] The post FY2021 EPS Estimates for Can-Fite BioPharma Ltd. Raised by Dawson James (NYSEAMERICAN:CANF) appeared first on ETF Daily News .

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week cycle of treatment with Pi

Can-Fite BioPharma (NYSEAMERICAN:CANF) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.19) EPS for the quarter, missing the Zacks consensus estimate of ($0.09) by ($0.10), Zacks reports. Can-Fite BioPharma had a negative net margin of 1,518.15% and a negative return on equity of 212.72%. CANF stock opened at $1.09 on Thursday. The []

Cannabis-focused biotech company Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) reported its financial results Friday for nine months ended September 30, 2021, with revenues of $650,000, compared

Can-Fite BioPharma Ltd (NYSE: CANF) has commenced a safety and efficacy study of Piclidenoson to treat osteoarthritis in dogs.  Safety results are expected in Q1 2022, and efficacy data is expecte

Shares of Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) traded up 0.4% during mid-day trading on Wednesday . The stock traded as high as $1.37 and last traded at $1.32. 223,523 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 1,352,068 shares. The stock had previously closed at $1.32. Separately, Zacks []

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address infla

Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021.

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specif

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study

Can-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to develop Piclidenoson to treat osteoarthriti

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addres